Susquehanna International Group’s Alder Biopharmaceuticals ALDR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-215,124
Closed -$4.06M 11232
2019
Q3
$4.06M Buy
215,124
+130,854
+155% +$1.5M ﹤0.01% 3015
2019
Q2
$992K Buy
+84,270
New +$1.02M ﹤0.01% 5680
2019
Q1
Sell
-24,728
Closed -$320K 10395
2018
Q4
$253K Buy
+24,728
New +$317K ﹤0.01% 7319
2018
Q3
Sell
-140,071
Closed -$2.53M 10733
2018
Q2
$2.21M Buy
140,071
+113,373
+425% +$1.72M ﹤0.01% 3838
2018
Q1
$339K Sell
26,698
-47,492
-64% -$687K ﹤0.01% 7419
2017
Q4
$849K Buy
74,190
+59,634
+410% +$666K ﹤0.01% 5567
2017
Q3
$178K Buy
+14,556
New +$152K ﹤0.01% 8103
2017
Q1
Sell
-12,124
Closed -$268K 10510
2016
Q4
$252K Buy
+12,124
New +$315K ﹤0.01% 8268
2016
Q1
Sell
-43,277
Closed -$1M 10012
2015
Q4
$1.43M Sell
43,277
-62,506
-59% -$2.11M ﹤0.01% 4699
2015
Q3
$3.46M Buy
105,783
+59,396
+128% +$2.53M ﹤0.01% 3250
2015
Q2
$2.46M Buy
46,387
+18,606
+67% +$677K ﹤0.01% 4264
2015
Q1
$802K Buy
+27,781
New +$762K ﹤0.01% 6199
2014
Q3
Sell
-11,251
Closed -$226K 10213
2014
Q2
$226K Buy
+11,251
New +$158K ﹤0.01% 8864

Susquehanna International Group's ALDR Position: Q4 2019 in Review

Susquehanna International Group sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 215,124 shares — an estimated $4.06M sold.

Susquehanna International Group first reported a position in ALDR in Q2 2014 and held it in 13 quarters. The position peaked at $4.06M in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

  • Susquehanna International Group reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Susquehanna International Group sold 215,124 Alder Biopharmaceuticals shares in Q4 2019, an estimated $4.06M.
  • Susquehanna International Group first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 13 quarters.
  • Susquehanna International Group's Alder Biopharmaceuticals position peaked at $4.06M in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Susquehanna International Group's 13F filing for Q4 2019, filed 14 Feb 2020.